Results 41 to 50 of about 10,095 (153)

Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib

Maxillofacial Plastic and Reconstructive Surgery, 2017
Background Imatinib mesylate is an inhibitor of the tyrosine kinase Bcr–Abl and a first-line treatment for Philadelphia chromosome-positive chronic myeloid leukaemia (CML).
Gian Paolo Bombeccari, Umberto Garagiola, Francesco Pallotti, Margherita Rossi, Massimo Porrini, Aldo Bruno Giannì, Francesco Spadari   +6 more
doaj   +1 more source

Real‐World Outcomes With Low‐Dose Dasatinib (50 mg) in Imatinib‐Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and Safety

Cancer Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background Dasatinib, a potent second‐generation tyrosine kinase inhibitor (TKI), is highly effective in chronic myeloid leukemia in chronic phase (CML‐CP) resistant to imatinib at standard dosing (100 mg daily), but is often limited by adverse events.
Nandhini Gangadaran, Harshal Mamlekar, Souvik Saha, Rajesh Kashyap, Sanjeev Yadav, Khaliqur Rahman, Ruchi Gupta, Mona Vijayaran, Manish Singh, Dinesh Chandra   +9 more
wiley   +1 more source

Beta Thalassemia and Chronic Myeloid Leukemia: Dual Diagnosis Under the Microscope

International Journal of Laboratory Hematology, EarlyView.
Paige Muir, Mohammad Bahmanyar, Hamish Nicolson, Hayley Merkeley   +3 more
wiley   +1 more source

Genetic Analysis of Imatinib Resistance in CML: The Role of T315I and E255K

Advances in Hematology, Volume 2026, Issue 1, 2026.
Background and Aims Imatinib mesylate is a small molecule inhibitor targeting the BCR‐ABL tyrosine kinase. However, some CML patients develop resistance to imatinib. This resistance is commonly associated with mutations in the kinase domain of BCR‐ABL, notably the prevalent T315I and E255K mutations.
Saba Yari, Reza Masoomi Jahandizi, Mehrdad Payandeh, Kimiya Dadashizadeh, Kalyani Sen   +4 more
wiley   +1 more source

Exploring the Therapeutic Mechanism of Xiehuo Pingtu San in Treating Thyroid Eye Disease Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation

International Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Background Xiehuo Pingtu San (XHPTS) has been shown to be safe and effective in treating thyroid eye disease (TED), yet its underlying mechanisms remain unclear. This study aimed to elucidate the active ingredients of XHPTS and their therapeutic mechanisms in TED through network pharmacology, molecular docking, and molecular dynamics simulations ...
Ping Wang, Ruiyan Liu, Xin Shang, Yu Fu, Ying Wang, Shuxun Yan, Suraiya Saleem   +6 more
wiley   +1 more source

High Shear Stress‐Induced Endothelial Piezo1 Downregulation Promotes Intracranial Aneurysm Formation via the PDGF‐BB/PDGFRβ Paracrine Signaling Pathway

CNS Neuroscience &Therapeutics, Volume 31, Issue 12, December 2025.
HSS downregulates Piezo1 expression in ECs, which subsequently enhances PDGF‐BB expression through the YAP/β‐catenin signaling pathway. The elevated PDGF‐BB facilitates phenotypic transition of VSMCs via PDGFRβ binding, ultimately contributing to IA formation.
Zhiwen Lu, Sisi Li, Fengfeng Xu, Haishuang Tang, Shijie Zhu, Chuanchuan Wang, Xiaohua Yang, Qinghai Huang   +7 more
wiley   +1 more source

A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens

Cancer, Volume 131, Issue 21, 1 November 2025.
ABSTRACT Advances in the prognostication, monitoring, and treatment of both the acute and chronic leukemias have led to drastically improved outcomes over the past 2 decades. With the advent of targeted therapies, including antibodies such as blinatumomab and inotuzumab and small molecule inhibitors, such as the BCR::ABL1 tyrosine kinase inhibitors ...
Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, Courtney DiNardo, Guillermo Garcia‐Manero, Ghayas Issa, Elias Jabbour, Nitin Jain, Tapan Kadia, Sanam Loghavi, Farhad Ravandi, Guilin Tang, Mary Alma Welch, William Wierda   +13 more
wiley   +1 more source

The Mechanisms of Imatinib Resistance in Gastrointestinal Stromal Tumours: Theoretical Basis and Therapeutic Aspect

Journal of Cellular and Molecular Medicine, Volume 29, Issue 21, November 2025.
ABSTRACT Imatinib is a small molecule that inhibits receptor tyrosine kinases KIT and platelet‐derived growth factor receptor α (PDGFRA). It was approved by the U.S. Food and Drug Administration (FDA) in 2002 for the treatment of advanced, unresectable gastrointestinal stromal tumours (GISTs). Since then, additional kinase inhibitors targeting multiple
Nuerbiye Abudurexiti, Yidan Lou, Mengqi Wu, Yingchen Huang, Shan Huang, Kaibo Guo, Song Zheng   +6 more
wiley   +1 more source

Imatinib resistance: diagnostic and therapeutic choices

Clinical Management Issues, 2015
We report a case of a 42-year-old woman with t(9;22) positive chronic myeloid leukemia (CML) who developed a sub-optimal response to therapy with imatinib mesylate due to M351T mutation and low plasma level of imatinib. Dose increase of imatinib resulted
Marianna De Muro, Odoardo Maria Olimpieri, Rosa Greco, Lidia Altomare   +3 more
doaj   +1 more source

Yttrium‐90 Selective Internal Radiotherapy for Gastrointestinal Stromal Tumor With Liver Metastasis: A Case Report and Review

Cancer Innovation, Volume 4, Issue 5, October 2025.
Therapeutic protocols are urgent for liver metastases in Gastrointestinal stromal tumors (GIST) patients. This article presents China's first case in GIST liver metastases patients, treating with Yttrium‐90 resin microsphere selective internal radiation therapy, reviews management challenges, and highlights the emerging role of novel therapies to ...
Li Xing, Xiaobin Feng, Lin Zhang, Zheng Mo, Zhuo Yu   +4 more
wiley   +1 more source